| scholarly article | Q13442814 |
| P50 | author | Marcus Hacker | Q28149000 |
| Oliver Langer | Q37830621 | ||
| Martin Bauer | Q48176743 | ||
| Wolfgang Wadsak | Q51059438 | ||
| Cecile Philippe | Q55098300 | ||
| Markus Alexander Zeitlinger | Q75261425 | ||
| P2093 | author name string | W Jäger | |
| W Löscher | |||
| A Maier-Salamon | |||
| B Wulkersdorfer | |||
| C Jungbauer | |||
| H Haslacher | |||
| J Stanek | |||
| K Römermann | |||
| R Karch | |||
| P2860 | cites work | P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide | Q33797745 |
| Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data | Q34100185 | ||
| Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography | Q34125735 | ||
| Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects | Q34356874 | ||
| Inhibiting drug efflux transporters improves efficacy of ALS therapeutics | Q34824777 | ||
| Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up | Q35720625 | ||
| Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar | Q35831488 | ||
| The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). | Q36015358 | ||
| Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography | Q36049576 | ||
| A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier | Q36386154 | ||
| Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor | Q36949086 | ||
| Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier | Q36949089 | ||
| Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. | Q36949815 | ||
| Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans | Q37369295 | ||
| Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. | Q38099191 | ||
| Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues | Q38200490 | ||
| Apical ABC transporters and cancer chemotherapeutic drug disposition. | Q38339766 | ||
| Overcoming the blood-brain tumor barrier for effective glioblastoma treatment | Q38384505 | ||
| Imaging the Impact of the P-Glycoprotein (ABCB1) Function on the Brain Kinetics of Metoclopramide. | Q38818377 | ||
| Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study | Q39213026 | ||
| Several major antiepileptic drugs are substrates for human P-glycoprotein | Q39934629 | ||
| Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study. | Q40308640 | ||
| Quantitative Analysis of the ABCG2 c.421C>A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model | Q41499980 | ||
| Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier | Q41775684 | ||
| Synthesis and evaluation of [11C]XR9576 to assess the function of drug efflux transporters using PET. | Q43111234 | ||
| Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone | Q43122836 | ||
| Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans. | Q44313286 | ||
| ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. | Q45993642 | ||
| An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amin | Q46213823 | ||
| Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography | Q46551897 | ||
| Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans | Q46826559 | ||
| P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan | Q46920680 | ||
| Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe | Q47744319 | ||
| Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil | Q48176609 | ||
| Evaluation of limiting brain penetration related to P-glycoprotein and breast cancer resistance protein using [(11)C]GF120918 by PET in mice | Q48243022 | ||
| The concept of fraction of drug transported (ft ) with special emphasis on BBB efflux of CNS and antiretroviral drugs | Q48335227 | ||
| Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. | Q49123419 | ||
| Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats. | Q50901303 | ||
| Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. | Q51014762 | ||
| Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. | Q52086788 | ||
| Local Drug-Drug Interaction of Donepezil with Cilostazol at Breast Cancer Resistance Protein (ABCG2) Increases Drug Accumulation in Heart. | Q52147924 | ||
| Interindividual Variability in the Hepatic Expression of the Human Breast Cancer Resistance Protein (BCRP/ABCG2): Effect of Age, Sex, and Genotype | Q57684358 | ||
| Ultrastructural study of the human neurohypophysis. III. Vascular and perivascular structures | Q71235822 | ||
| Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria | Q80548014 | ||
| Genotyping using the TaqMan assay | Q81130441 | ||
| Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors | Q83364209 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | blood–brain barrier | Q221694 |
| P304 | page(s) | 131-141 | |
| P577 | publication date | 2016-03-03 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier | |
| P478 | volume | 100 |
| Q36338999 | A Prediction Method for P-glycoprotein-Mediated Drug-Drug Interactions at the Human Blood-Brain Barrier From Blood Concentration-Time Profiles, Validated With PET Data. |
| Q90609524 | Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches |
| Q57792155 | Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET |
| Q92649497 | Age-Related Functional and Expressional Changes in Efflux Pathways at the Blood-Brain Barrier |
| Q91942754 | Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography |
| Q36054570 | Early-life metal exposure and schizophrenia: A proof-of-concept study using novel tooth-matrix biomarkers |
| Q38841102 | Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[11 C]verapamil in elderly vs. young subjects. |
| Q39290800 | Efflux proteins at the blood-brain barrier: review and bioinformatics analysis |
| Q38871905 | Imaging transporters: Transforming diagnostic and therapeutic development |
| Q99613968 | Impaired clearance from the brain increases the brain exposure to metoclopramide in elderly subjects |
| Q91322925 | Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients? |
| Q37699375 | MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1. |
| Q47944360 | Obstacles to Brain Tumor Therapy: Key ABC Transporters |
| Q57137963 | Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration |
| Q98476068 | Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment |
| Q91130089 | Proof-of-Concept Study of Drug Brain Permeability Between in Vivo Human Brain and an in Vitro iPSCs-Human Blood-Brain Barrier Model |
| Q91003266 | Protein Expression and Functional Relevance of Efflux and Uptake Drug Transporters at the Blood-Brain Barrier of Human Brain and Glioblastoma |
| Q48105538 | Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach |
| Q52593092 | Revisiting the role of ABC transporters in multidrug-resistant cancer. |
Search more.